Cargando…
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
IMPORTANCE: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%, respectively, with adjuvant fluorouracil and oxaliplatin–based chemotherapy; however, the trial did not demonst...
Autores principales: | Chibaudel, Benoist, Henriques, Julie, Rakez, Manel, Brenner, Baruch, Kim, Tae Won, Martinez-Villacampa, Mercedes, Gallego-Plazas, Javier, Cervantes, Andres, Shim, Katharine, Jonker, Derek, Guerin-Meyer, Veronique, Mineur, Laurent, Banzi, Chiara, Dewdney, Alice, Dejthevaporn, Thitiya, Bloemendal, Haiko J., Roth, Arnaud, Moehler, Markus, Aranda, Enrique, Van Cutsem, Eric, Tabernero, Josep, Schmoll, Hans-Joachim, Hoff, Paulo M., André, Thierry, de Gramont, Aimery |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573695/ https://www.ncbi.nlm.nih.gov/pubmed/33074326 http://dx.doi.org/10.1001/jamanetworkopen.2020.20425 |
Ejemplares similares
-
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
por: Auclin, Edouard, et al.
Publicado: (2019) -
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
por: Diouf, Momar, et al.
Publicado: (2014) -
STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2015) -
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016) -
Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report
por: Van Cutsem, Eric, et al.
Publicado: (2017)